The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
120
Oral administration
Oral administration
Neurocrine Clinical Site
Kazanlak, Bulgaria
RECRUITINGNeurocrine Clinical Site
Pazardzhik, Bulgaria
RECRUITINGNeurocrine Clinical Site
Targovishte, Bulgaria
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 35
Time frame: Day 35
Number of Participants With Treatment-emergent Adverse Event (TEAEs)
Time frame: Day 1 up to Day 49
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Neurocrine Clinical Site
Târgu Mureş, Romania
RECRUITINGNeurocrine Clinical Site
London, United Kingdom
RECRUITINGNeurocrine Clinical Site
Oxford, United Kingdom
RECRUITING